

REFERENCES

- Abdel-Aziz F., Habib M. and Mohamed M.K. (2000):*** "Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence". *Hepatology*; 32: 111-115.
- Adler R.A. and Rosen C.J. (1994):*** "Glucocorticoids and osteoporosis" *Endocrinol Metab. Clin*; 23:641-654.
- Alter H.J., Peck N. and Seeff L.B. (2002):*** "Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome". *Seminars in liver Dis*; 20(1): 17-35.
- Angelico G., Renganathan M. and Gandin C. (1997):*** "Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistomiasis and hepatitis virus infections". *Hepatology*. J.; 26: 236-243.
- Anne K. (2001):*** "NIH Consensus development panel on osteoporosis prevention, diagnosis, and therapy". *JAMA*, February 14, Vol. 285, No. 6.
- Armstrong G.L., Wasley A., Simard E.P. and McQuillan G.M. (2002):*** "The prevalence of hepatitis C virus infection in the United States, 1999 through 2002". *Ann. Intern. Med.*; 144: 705-714.

- Arthur R., Hassan N. and Abdallah M. (1997):** "Hepatitis C antibody prevalence in blood donors in different governorates in Egypt". Trans. R. Soc. Trop. Med. Hyg.; 91:271-274.
- Bacon B.R. (2002):** "Treatment of patients with hepatitis C and normal serum aminotransferase levels". 36 (5 suppl.1): p179-184.
- Bagur A., Mautalen C., Findor J., Sorda J. and Somoza J. (1998):** "Risk factors for the development of vertebral and total skeleton osteoporosis in patients with primary biliary cirrhosis". Calcif. Tissue Int; 63:385-390.
- Becker C. (2003):** "Clinical Evaluation for osteoporosis". Clinics in Geriatric Medicine; 19:807.
- Bell H., Raknerud N., Falch J.A. and Haug E. (1995):** "Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis". Eur. J. Endocrinal.; 132:444-449.
- Bernstein C.N., Blanchard J.F. and Leslie W. (2000):** "The incidence of fracture among patients with inflammatory bowel disease. A population – based cohort study". Ann Intern Med; (133):793-799.
- Bhalla A.K. (1998):** "Osteoporosis and osteomalacia". Oxford textbook of rheumatology (2nd edition): Maddison PJ, Isenberg DA, Woo P and Glass DN (editors). Oxford University Press, New York; P. 1583.
- Black DM., Ciccozzi M .and Achemlal L. (2000):** "Fracture risk reduction with alendronate in women with osteoporosis" The Fracture Intervention Trial; J. Endocrinol. Metab. 85:4118-24.

- Brunader R and Shelton D.K (2002):*** "Radiologic Bone Assesement in the Evaluation of Osteoporosis". American Family Physician; 65 (7): 403.
- Bruno S., Silini E., Crosignani A. and Borzio F. (1997):*** "Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study". Hepatol. J.; 25(3): 754-8.
- Brunt E.M. (2000):*** "Nonalcoholic steatohepatitis: definition and pathology". Semin. Liver Dis.; 21:3-16.
- Cacooub P., Reno U. And Rosenthal E. (2000):*** "extra-hepatic manifestations associated with hepatitis C virus" e-medicine; (79):47-56.
- Campbell M. and Reddy K. (2004):*** "The Evolving Role of Liver Biopsy" Aliment Pharmacol Ther.; 20(3):249-259.
- Carey E.J. and Balan V. (2003):*** "Osteopaenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem" Liver Transpl; 9:1166-1173.
- Cayco A.V., Wysolmerski J. and Simpson C. (2000):*** "Posttransplant bone disease: evidence for a high bone resorption state" Liver Transpl.; 70:1722.
- Cijevschi S., Doneray H. and Orbak Z. (2005):*** "association between bone turnover markers and BMD in puberty" West Indian med.J.; vol.57:301-306.

- Cockayne S., Adamson J., Lanham-New S., Shearer M.J., Gilbody S. and Torgerson D.J. (2006):** "Vitamin K and the prevention of fractures". Arch. Intern. Med.; 166:1256-1261.
- Collier J. (2007):** "Bone Disorders in Chronic Liver Disease" hepatology J.; Vol. 46, No. 4, P 1271:1287
- Collier J.D., Ninkvic M. and Compston J.E. (2002):** "Guidelines on the management of osteoporosis associated with chronic liver disease" Gut; 50 (1): 11.
- Davis G.L. (1999):** "Hepatitis C virus" Lippincott-Raven, Philadelphia; (8th edition):793-836.
- Delaney M. and LeBoff M. (2001):** "Metabolic bone disease". In: Kelley's textbook of rheumatology (6th edition); vol. 2: p. 1635.
- Dequeker J. and Mundy G. (1998):** "Bone structure and function". In: Rheumatology (2nd edition). Kipple JH and Dieppe P (editors). Mosby, London; P831-336.
- Di Bisceglie A.M. (2006):** "Hepatitis C".Clinical Hepatology; 2:235-248.
- Di Bisceglie A.M. and Hoofnagle J.H. (2002):** "Optimal therapy of hepatitis C". Hepatology; 36 (5 suppl.1): S121-S127.
- Dienstag J.L. and Mc Hutchison J.G. (2006):** "American Gastroenterological Association technical review on the management of hepatitis C". Gastroenterology; 130:231-264; quiz 14: 17.
- Duarte M.P., Farias M.L. and Coelho H.S. (2001):** "Calcium – parathyroid hormone – vitamin D axis and metabolic bone disease

in chronic viral liver disease". Journal of Gastroenterology and hepatology; 16:1022.

Eastell R. (1998): "Treatment of postmenopausal osteoporosis". N Engl J Med.; 12: 338-736.

Einhorn T.A. (1993): "Bone metabolism and metabolic bone disease". In: Frymoyer TW, ed. Orthopedic Knowledge update. Park Ridge, Illinois: Am. Acad. Orthop. Surg.: p 69-88.

El din M., Hassan A., Regheb M. and Rageh F. (2006): "Prevalence and risk factors of Osteoporosis in Chronic Hepatitis and Cirrhosis" Afro-Arab Liver J.; (Vol. 5):p53.

El Nasr M. (2005): Study of osteoporosis in patients with liver cirrhosis. Menoufiya University; 98:p103.

El-Zayadi A., Abaza H. and Shawky S. (2001): "Prevalence and epidemiological features of hepatocellular carcinoma in Egypt- a single centre experience". Hepatol. Res.; 19:170-179.

El-Zayadi A., Simmonds A. and Dabbous H. (1996): "Response to interferon- α of Egyptian patients infected with hepatitis C virus genotype 4". J. Viral Hepatitis; 3:261-264.

El-Zayadi A.R., Attia M. and Barakat E.M. (2005): "Response of hepatitis C genotype-4 native patients to 24 weeks of Peginterferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study" Am. J. Gastroenterol.; 100:2447-2452.

- Emilio O., Loyola A. and Satio N. (2005):** "University of chigacostritch school of medicine, hepatitis virus C prevelance " j. hepatol.; 38:234-237.
- Ezzat W., Raslan H., Mokhles M., and abdel-rasheed E. (2007):** "Bone mineral density and bone turnover in chronic liver disease" J.Med. Sci.; 7 (5): 748-754.
- Feld J.J. and Hoofnagle J.H. (2005):** "Mechanism of action of interferon and ribavirin in treatment of hepatitis C ". Nature; 436: 967-972.
- Ferrero S., Lungaro P., Bruzzone B.M. and Gotta C. (2003):** "Prospective study of mother-to-infant transmission of hepatitis C virus: a ten year survey (1990-2000)". Acta. Obstet. Gynecol. Scand; 82: 229-234.
- Flamm S.L., Parker R.A. and Chopra S. (1998):** "Risk factors associated with chronic hepatitis C virus infection: limited frequency of an unidentified source of transmission". Am. J. Gastroenterol.; 93: 597-600.
- Francois MP., Alter M.J. and Kuntzen T. (2003):** "Bone densitometry testing on non white patients" JAMA Feb. 26; 289(8):982.
- Frank C., Mohamed M., lavenchy D. and Strickland G. (2000):** "the role of parenteral antischisosomal therapy in the spread of hepatitis C in Egypt" lancet; 335 (9207):887-91.

- Fried M.W., Shiffman M.L. and Reddy K.R. (2002):** "Peginterferon alpha2a plus ribavirin for chronic hepatitis C virus infection" N. Engl. J. Med.:347:975-982.
- Friedman S. and Keefe B. (2004):** "Cirrhosis and portal hypertension" In Friedman S, Keefe B. "Hand Book of Liver disease"; p125-132.
- Ganong W. (2001):** "Hormonal control of calcium metabolism & the physiology of bone". In: Review of medical physiology (20th edition). Ganong WF (editor). Middle East edition. A Lange medical book. Appelton and Lange. Libraire du liban, Lebanon.; p. 369.
- Goral V., Simsek M. and Mete N. (2010):** "Hepatic osteodystrophy and liver cirrhosis" World J. Gastroenterol 7; 16(13): 1639-1643.
- Green W.B. (2001):**"essentials of musculoskeletal care" American acad. Ortho. Surg.; 2nd edition: 234-251.
- Grexi I., Laffi G. and Zignego A. (2008):**" hepatitis C virus infection" mol. aspects Med. ;(29):85-95.
- Hahn J.A. (2007):** "Sex, drugs and Hepatitis C virus". J. Infect. Dis.; 195: 1556-9.
- Hassan M., Zaghloul A. and El-Serag H. (2001):** "The role of hepatitis C in hepatocellular carcinoma – a case control studies among Egyptian patients". J. Clin. Gastro.; 33:123-126.
- Healy (1995):** "Glucocorticoids induced osteoporosis". Curr. Opin. Orthop. ;5:33-88.

- Hofmann W., Kronenberg J., Stamm E., Mihm M. and Zeuzem C. (2008):** "prospective study of BMD and metabolism in patients with chronic HCV during pegylated interferone alpha" J. viral hepat.;15(11):790-796.
- Hoofnagle J.H. (2002):** "Course and outcome of hepatitis C". Hepatology; 36 (5 suppl.1): S21-S29.
- Hurley D.L. (1987):** "Axial and appendicular bone mineral density in patients with long term deficiency or excess of calcitonin". N. Engl. J. Med. 317; 537.
- Jacob D., Hobar C. and Shanmugam S. (2010):** "Osteoporosis: Treatment & Medication ". eMedicine Specialties -Rheumatology - Metabolic and Bone Disease.
- Kamal S.M. and Nasser I.A. (2008):** "Hepatitis C genotype 4: What we know and what we don't yet know". Hepatology. 2008; 47(4):1371-83.
- Kamal S.M., Fouly A.E., Kamel R.R. and Hockenjos B. (2006):** "Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response".Gastroenterology; 130(3):632-8.
- Karan M.A., Etren N. and Tasciolgu C. (2001):** "Osteodystrophy in Posthepatitic Cirrhosis". Yonsei Med. J.; Vol. 42, No. 5:547-552.
- Karmochkine M., Carrat F., Santos D.O., Cacoub P. and Raguin G. (2006):** "A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection". J. Viral Hepat.; 13(11): 775-82.

- Klibanski A., Adams L. and Bassford T. (2000):** "Osteoporosis Prevention, Diagnosis, and Therapy". Am NTH Consens Statement March 27-29; 17 (1): 1.
- Kumar P. and Clark M. (2009):** "Liver, biliary tract and pancreatic disease". In Clinical medicine (7th ed.) Kumar P and Clark M (editors). W.B. Saunders, London; 334.
- Lane N.E. (1998):** "Risk factors for osteoporosis". In: Rheumatology (2nd edition). Kipple J H and Dieppe P (editors). Mosby, London; P. 838-891.
- Lau E.M. (2001):** "Epidemiology of osteoporosis". Best Pract. Res. Clin. Rheumatol J.; 15(3): 335.
- Lavanchy D. (1999):** "Global surveillance and control of hepatitis C". J. Viral Hepat.; 6: 35-47.
- Lindenbach B.D. and Rice C.M. (2005):** "Unraveling hepatitis C virus replication from genome to function". Nature; 436:933-938.
- Liovet M., Beaguard M. and Lucy N. (2003):**"Hepatocellular carcinoma: present status and future prospect" .J. hepatol.; 38:136-149.
- Liu S., Yan H., Li J. and Zhu B. (2009):** "correlation analysis between bone mineral density and serum element contents of postmenopausal women in Xi an urban area". Biol. trace Elem. res.; 131(3):205-14.
- Mahdy K., Ahmed N., Mannaa F. and Abdel- sheded A.(2007):** "clinical benefits of biochemical markers of bone turn over in egyptian children with CLD". World gastro.; 13(5):785-790.

- Marcus (1988):** "Endocrine control of bone and mineral metabolism". In Manolagas (eds): Metabolic bone and mineral disorders. New York, Churchill Livingstone, p 13.
- Margaret L. (2004):** "Clinical consideration in premenopausal osteoporosis". Arch. Int. Med.; Vol. 164 p: 603-606.
- Mehmet A.K., Nilgum E., and Cemil T. (2001):** "Osteodystrophy in Posthepatic Cirrhosis". Yonsie Medical Journal; 42(5): 547.
- Menon W., Kawlsky N., Stenstonberg W. and Kally S. (2001):**"bone metabolic changes among patients with CLD" J. Endocrinol. Metab.; 86:3242-49.
- Michael H.R. (2005):** "Histology, A text & Atlas, with cell & molecular biology"; Forth edition : p186-92.
- Mohamed M.K. (2004):** "Epidemiology of HCV in Egypt". The Afro-Arab Liver Journal; 3(2):41-52.
- Mohamed M.K., Abdel-Hamid M., Mikhail N.N. and Abdel-Aziz F. (2005):** "Intrafamilial transmission of hepatitis C in Egypt". Hepatology; 42: 683-687.
- Mokhtar S. and Hamed S. (2006):** "Bone mineral density in Egyptian cirrhotic patients". Liver Int. J.; (Vol 26): p43.
- Morrison N.A., Qi J.C., Tokita A., Kelly P. and Sambrook P.N. (1994):** "Prediction of bone mineral density from vitamin D receptor alleles". Nature; 367:284-287.

- Moschen A.R., Kaser A., Kaser S. and Muhlleschner P. (2005):** "The RANKL/OPG system and bone mineral density in patients with chronic liver disease". J. Hepatol.; 43:973-983.
- Ormarsdottir S, Ljunggren O and Mallmin H (2001):** "Inverse relationship between circulating levels of leptin and bone mineral density in chronic liver disease". Euro J. Gastroenterol. Hepatol. Dec; 16(12): 1409-14.
- Palmer M. (2004):** "Guide of hepatitis and liver disease".
<http://www.product.half.ebay.com/-W0QQprZ30449308>.
- Pares A. and Guanabens N. (2006):** "Treatment of bone disorders in liver disease". J. Hepatol.; 45:445-453.
- Pawlotsky J.M., Chevalier S. and McHutchinson J.G. (2007):** "The hepatitis C virus life cycle as a target for new antiviral therapies". Gastroenterology; 132:1979-1998.
- Penin F., Dubuisson J., Rey F.A. and Moradpour D. (2004):** "Structural biology of hepatitis C virus". Hepatology.; 39:5-19.
- Perz J.F., Armstrong G.L. and Farrington L.A. (2006):** "The contribution of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide". J. Hepatol.; 45: 529-538.
- Pongchaiyakul C., Kosulwat V., Charoenkiatkul S. and Chailurkit L. (2008):** "The Association of Dietary Calcium, Bone Mineral Density and Biochemical Bone Turnover Markers in Rural Thai Women" j. Med Assoc. Thai 2008; 91 (3): 295-302.

- Ray S., Arthur R. and Carella A. (2004):** "Genetic epidemiology of hepatitis C virus throughout Egypt". J. Infect. Dis.; 182:698-707.
- Roger M.A. (1996):** "The musculoskeletal system". In: Mercer's orthopedic surgery (9th edition). Robert BD and Gerorge B (editors). Churchill Livingstone, London; Vol. 1: P. 43.
- Rosen C.J. (2000):** "Pathophysiology of osteoporosis". Clin. Lab. Med.; 20(4): 455.
- Rouillard S. And Lane N.E. (2001):** "Hepatic Osteodystrophy". Hepatology; Vol. 33, No. 1: P. 301-307.
- Rubin C. and Rubin J. (2001):** "Disorders of bone and structural protein". In: Kelley's Textbook of rheumatology (6th edition). Ruddy S. Harris E and Sledge C (editors). Saunders Company, Philadelphia; P. 1611.
- Saito N., Tabata N., saito S., onga Y. and hori T. (2004):** "bone mineral density, serum albumin and serum maganesium" j. of American college of nutrition; vol.23 No. 6: 701-703.
- Sambrook P. and Cooper C. (2006):** "Osteoporosis". Lancet; 37:2010-2018.
- Schiefke I., Fach A., Wiedmann M., Eva Schenker A. and Borte G. (2005):** "Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection" World J. Gastroenterol 2005; 11(12): 1843-1847.
- Schiff E.R. (1997):** "Hepatitis C and alcohol". Hepatol; 26(3 Suppl 1): 39S-42S.88.

- Schwartz A.V., Sellmeyer D.E. and Ensrud K.E. (2001):** "Older Women with diabetes have an increased risk of fracture: a prospective study". J. Clin. Endocrinol Metab; 86:131.
- Scott G. (2010)"** Is Strontium Useful for Osteoporosis?" Medscape Pharmacists.
- Selby P.L., Davies M. and Adams J.E. (1999):** "Bone loss in celiac disease is related to secondary hyperparathyroidism". J. Bone Miner. Res.; 14:652.
- Semeao E.J., Stallings V.A. and Peck SN (1997):** "Vertebral compression fractures in pediatric patients with Crohn's disease". Gastroenterology; 112:1710.
- Shepard C.V., Finelli L., Fiore A.E. and Bell B.P. (2005):** "Epidemiology of hepatitis B and hepatitis C virus infection in United States children". Pediatr. Infect. Dis. J.; 24: 755-760.
- Shiomi S., Masaki K., Habu D. and Takeda T. (1999):** "Calcitriol for bone loss in patients with primary biliary cirrhosis". J Gastroenterol.; 34:241-245.
- Shobokshi O., Serebour E. and Skakni L. (1999):** "Hepatitis C genotypes and subtypes in Saudi Arabia". J. Med. Virol.; 58:44-48.
- Simonet W.S., Lacey D.L., Dunstan C.R. and Kelley M. (1997):** "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density". Cell j.; 89:309-319.
- Sinak M., Findor J. and Jacob D. (2002):** "Stronger back muscles reduce the incidence of vertebral fracture: A prospective 10 years follow up of postmenopausal women Bone"; 30:836-841.

- Smith EL., Nilgum E. and Mounach A. (2006):** "Physical activity and calcium modalities for bone mineral increase in old women". *Med. Sci. Sport. Exerc*; 13:60-64.
- Spada E., Mele A., Ciccozzi M. and Tosti M.E. (2001):** "Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy". *Dig. Liver Dis*; 33: 778-784.
- Stenstrom M.G., Norjavaara E. and Hulten L. (2001):** "Late normal puberty in men is associated with lower bone mass in spine and hip at 21 years of age". *J. Bone Miner Res.*; 16 (suppl 1):185
- Steven R., Ghaffar Y.A., Mounach A. and Scott D. (2005):** "New technologies in the spine". Lippincott Williams & Willkins Inc., Spine; Vol. 26:1511-1515.
- Stevens A. (2005):** "Human histology, Bone". Third edition, Mosby, London: p251-64.
- Strader D.B., Wright T. and Thomas D.L. (2004):** "ASSLD practice guideline: diagnosis, management, and treatment of hepatitis C". *Hepatology J.*; 39:1147-1171.
- Sulkowski M.S. and Thomas D.L. (2003):** "Hepatitis C in the HIV-infected person". *Ann. Intern. Med.*; 138:197-200.
- Thompson S., Hernberger F., Wale E. and Crofts N. (2006):** "Hepatitis C transmission through tattooing: a case report". *Aust. N Z J Public Health*; 20 (3): 317-8.

- Timm J., Neukamm M., Kuntzen T. and Kim A.Y. (2007):** "Partners AIDS Research Center, Infectious Disease Division, Massachusetts General Hospital, Boston, MA, USA". *Viral Hepat.*; 14(5): 330-7.
- Uretman S., Gol M. and Cimrin D. (2005):** "Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women". *Eur. J. Obstet. Gynecol .Reprod Biol.*; vol 123 (issue 1): p 67-71.
- Van der M.W., Van den Bgaede J.B. and Goosen C. (2003):** "Hepatic osteodystrophy in rats results mainly from porto-systemic shunting". *Gut*; 52:580-585.
- Veldt B., Chen W. and Healthcot T. (2007):** "Increase incidence of hepatocellular carcinoma among patients with C cirrhosis" *hepatology.J.*; 47(6): 773-81.
- Villano S.A., Vlahov D., Cohn S. and Thomas D.L. (1999):** "Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection". *Hepatology j.*; 29(3): 908-14.
- Voyer M., Nobre R. and Magny J.F. (2001):** "Breast-feeding and hepatitis C virus (HCV): the need for a careful appraisal". *Arch. Pediatr*; 8(1): 66-77.
- Walsh L.J. and Tattersfield A.E. (1997):** "Bone disease in asthma". *BR J Hosp. Med.* 1997; 57:390.
- Wang J.H., Changchien C.S. and Hung C.H. (2009):** "Fibro Scan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis". *J. Gastroenterol.*; 44(5):439-46.

- Wariaghli G., Mounach A., Achemlal L. and Benbaghdadi I. (2009):** "Osteoporosis in chronic liver disease: a case-control study" *Rheumatol Int.J.*;10: 12-56.
- Wasley A. and Alter M.J. (2000):** "Epidemiology of hepatitis C: geographic differences and temporal trends". *Semin. Liver Dis.*; 20:1-16.
- Wiegand J., Buggisch P., Boecher W., Zeuzem S. (2006):** "Early monotherapy with pegylated interferon alfa-2b for acute hepatitis C infection: The HEP-NET Acute HCV-II Study". *Hepatology J.*; 43(2): 250–256.
- World Health Organization (1997):** "Hepatitis C: global prevalence". *Weekly epidemiological record*; 72:341-344.
- World Health Organization (2000):** "Hepatitis C- Global Surveillance Update". *Weekly Epidemiological Record*; 75: 17-28.
- World Health Organization (2000):** "Task-force for osteoporosis". *Osteoporos. Int.*; 10:259-264.
- Yenice N., Gumrah M., Kozan A. and Turkmen S. (2006):** "Assessment of bone metabolism and mineral density in chronic viral hepatitis" *Turk. J. Gastroenterol*; 17 (4): 260-266.
- Young J.W. (2003):** "Metabolic and endocrine disorders affecting bone". In: *Textbook of radiology and imaging* (7th ed.) Sutton D (editor). Churchill Livingstone, London; P. 1351.
- Zignego A.L., Ferri C., Caini P. and Bianchi F.B. (2006):** "For the Italian Association of the Study of Liver (A.I.S.F.) Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic

manifestations of Hepatitis C virus infection". Dig. Liver Dis.: p
23.